Abstract
Staphylococcus aureus is one of the most important pathogens causing chronic biofilm infections. These are becoming more difficult to treat owing to drug resistance, particularly because S. aureus biofilms limit the efficacy of antimicrobial agents, leading to high morbidity and mortality. In the present study, we screened for inhibitors of S. aureus biofilm formation using a natural product library from the Korea Chemical Bank (KCB). Screening by crystal violet-based biomass staining assay identified hit compounds. Further examination of antibiofilm properties of these compounds was conducted and led to the identification of celastrol and telithromycin. In vitro, both celastrol and telithromycin were toxic to planktonic S. aureus and also active against a clinical methicillin-resistant S. aureus (MRSA) isolate. The effect of the compounds on preformed biofilms of clinical MRSA isolates was evaluated by confocal laser scanning microscopy (CLSM), which revealed the absence of typical biofilm architecture. In addition, celastrol and telithromycin inhibited the production of extracellular protein at selected sub-MIC concentrations, which revealed the reduced extracellular polymeric substance (EPS) secretion. Celastrol exhibited greater cytotoxicity than telithromycin. These data suggest that the hit compounds, especially telithromycin, could be considered novel inhibitors of S. aureus biofilm. Although the mechanisms of the effects on S. aureus biofilms are not fully understood, our data suggest that telithromycin could be a useful adjuvant therapeutic agent for S. aureus biofilm-related infections.
Similar content being viewed by others
References
Actis L, Srinivasan A, Lopez-Ribot JL et al (2015) Effect of silver nanoparticle geometry on methicillin susceptible and resistant Staphylococcus aureus, and osteoblast viability. J Mater Sci Mater Med 26:215
Adam B, Baillie GS, Douglas LJ (2002) Mixed species biofilms of Candida albicans and Staphylococcus epidermidis. J Med Microbiol 51:344–349
Ando E, Monden K, Mitsuhata R et al (2004) Biofilm formation among methicillin-resistant Staphylococcus aureus isolates from patients with urinary tract infection. Acta Med Okayama 58:207–214
Arizza V, Vazzana M, Schillaci D et al (2013) Gender differences in the immune system activities of sea urchin Paracentrotus lividus. Comp Biochem Physiol A Mol Integr Physiol 164:447–455
Baker MA, Assis SL, Higa OZ, Costa I (2009) Nanocomposite hydroxyapatite formation on a Ti–13Nb–13Zr alloy exposed in a MEM cell culture medium and the effect of H2O2 addition. Acta Biomater 5:63–75
Beenken KE, Dunman PM, McAleese F et al (2004) Global gene expression in Staphylococcus aureus biofilms. J Bacteriol 186:4665–4684
Brady R, Leid J, Costerton J, Shirtliff M (2006) Osteomyelitis: clinical overview and mechanisms of infection persistence. Clin Microbiol Newsletter 28:65–72
Brown MR, Allison DG, Gilbert P (1988) Resistance of bacterial biofilms to antibiotics: a growth-rate related effect? J Antimicrob Chemother 22:777–780
Chambers HF (2001) The changing epidemiology of Staphylococcus aureus? Emerg Infect Diseases 7:178–182
Chambers HF, Deleo FR (2009) Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol 7:629–641
Chanda SK, Caldwell JS (2003) Fulfilling the promise: drug discovery in the post-genomic era. Drug Discov Today 8:168–174
Chopra I (2003) Antibiotic resistance in Staphylococcus aureus: concerns, causes and cures. Expert Rev Anti-Infect Ther 1:45–55
Christensen GD, Simpson WA, Younger JJ et al (1985) Adherence of coagulase-negative staphylococci to plastic tissue culture plates: a quantitative model for the adherence of staphylococci to medical devices. J Clin Microbiol 22:996–1006
Clinical and Laboratory Standards Institute (CLSI) (1999) Methods for determining bactericidal activity of antimicrobial agents; approved guideline M26-A. Wayne, PA
Clinical and Laboratory Standards Institute (CLSI) (2013) Performance standards for antimicrobial susceptibility testing. In: 23rd informational supplement, Wayne, PA
Cortés ME, Jessika CB, Ruben DS (2011) Biofilm formation, control and novel strategies for eradication. In: Méndez-Vilas A (ed) Science against microbial pathogens: communicating current research and technological advances, Formatex Research Center, Badajoz, vol 2, pp. 896–905
Darouiche RO (2004) Treatment of infections associated with surgical implants. N Engl J Med 350:1422–1429
Davey ME, O’Toole GA (2000) Microbial biofilms: from ecology to molecular genetics. Microbiol Mol Biol Rev 64:847–867
Donlan RM, Costerton JW (2002) Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 15:167–193
Flemming H-C, Wingender J (2010) The biofilm matrix. Nat Rev Micro 8:623–633
Gopal R, Kim YG, Lee JH et al (2014) Synergistic effects and antibiofilm properties of chimeric peptides against multidrug-resistant Acinetobacter baumannii strains. Antimicrob Agents Chemother 58:1622–1629
Graziano TS, Cuzzullin MC, Franco GC et al (2015) Statins and antimicrobial effects: simvastatin as a potential drug against Staphylococcus aureus biofilm. PLoS One 10:e0128098
Grundmann H, Aires-de-Sousa M, Boyce J, Tiemersma E (2006) Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat. Lancet 368:874–885
Hassan A, Usman J, Kaleem F et al (2011) Evaluation of different detection methods of biofilm formation in the clinical isolates. Braz J Infect Dis 15:305–311
Klevens RM, Morrison MA, Nadle J et al (2007) Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298:1763–1771
Kumon H, Tomochika K, Matunaga T et al (1994) A sandwich cup method for the penetration assay of antimicrobial agents through Pseudomonas exopolysaccharides. Microbiol Immunol 38:615–619
Li JW, Vederas JC (2009) Drug discovery and natural products: end of an era or an endless frontier? Science 325:161–165
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275
Maki DG, Tambyah PA (2001) Engineering out the risk for infection with urinary catheters. Emerg Infect Dis 7:342–347
Nandakumar V, Chittaranjan S, Kurian VM, Doble M (2013) Characteristics of bacterial biofilm associated with implant material in clinical practice. Polym J 45:137–152
National Institue of Health (NIH) (2003) Research on microbial biofilms: PA Number: PA-03-047. http://grants.nih.gov/grants/guide/pa-files/PA-03-047.html
Nosyk O, ter Haseborg E, Metzger U, Frimmel FH (2008) A standardized pre-treatment method of biofilm flocs for fluorescence microscopic characterization. J Microbiol Methods 75:449–456
Ooi N, Eady EA, Cove JH, O’Neill AJ (2015) Redox-active compounds with a history of human use: antistaphylococcal action and potential for repurposing as topical antibiofilm agents. J Antimicrob Chemother 70:479–488
Otto M (2004) Virulence factors of the coagulase-negative staphylococci. Front Biosci 9:841–863
Pearson RD, Steigbigel RT, Davis HT, Chapman SW (1980) Method for reliable determination of minimal lethal antibiotic concentrations. Antimicrob Agents Chemother 18:699–708
Qin C, Tan KL, Zhang CL et al (2012) What does it take to synergistically combine sub-potent natural products into drug-level potent combinations? PLoS One 7:e49969
Rice SA, McDougald D, Kumar N, Kjelleberg S (2005) The use of quorum-sensing blockers as therapeutic agents for the control of biofilm-associated infections. Curr Opin Investig Drugs 6:178–184
Sharma A, Rogers C, Rimland D et al (2013) Post-discharge mortality in patients hospitalized with MRSA infection and/or colonization. Epidemiol Infect 141:1187–1198
Shirtliff ME, Mader JT, Camper AK (2002) Molecular interactions in biofilms. Chem Biol 9:859–871
Silva S, Costa EM, Horta B et al (2016) Anti-biofilm potential of phenolic acids: the influence of environmental pH and intrinsic physico-chemical properties. Biofouling 32:853–860
Stewart PS (1994) Biofilm accumulation model that predicts antibiotic resistance of Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 38:1052–1058
Stewart PS (2002) Mechanisms of antibiotic resistance in bacterial biofilms. Int J Med Microbiol 292:107–113
Stewart PS, Costerton JW (2001) Antibiotic resistance of bacteria in biofilms. Lancet 358:135–138
Tacconelli E, De Angelis G, Cataldo MA et al (2008) Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis. J Antimicrob Chemother 61:26–38
Yarwood JM, Schlievert PM (2003) Quorum sensing in Staphylococcus infections. J Clin Invest 112:1620–1625
Zimmerli W, Trampuz A, Ochsner PE (2004) Prosthetic-joint infections. N Engl J Med 351:1645–1654
Acknowledgements
This study was supported by the Soonchunhyang University Research Fund and by Basic Science Research Program, through the National Research Foundation of Korea, funded by the Ministry of Education (NRF-2015R1D1A1A02061773).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Electronic supplementary material
Fig. S1
Representation of high-throughput screening for inhibitors of S. aureus ATCC 29213 biofilm formation. After screening at 250 μmol/L, compound activities were confirmed at 5 μmol/L (a). Results are expressed as percentage inhibition compared with controls lacking the compound. Triangle and square symbols indicate celastrol and telithromycin, respectively. Chemical structures of celastrol (left) and telithromycin (right) (b) (GIF 170 kb)
Rights and permissions
About this article
Cite this article
Woo, SG., Lee, SY., Lee, SM. et al. Activity of novel inhibitors of Staphylococcus aureus biofilms. Folia Microbiol 62, 157–167 (2017). https://doi.org/10.1007/s12223-016-0485-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12223-016-0485-4